REPAIR Impact Fund

The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund invests in companies involved in discovering and early-stage development of therapies targeting resistant microorganisms. It was established by Novo Holdings to replenish the anti-infective pipeline and to combat antimicrobial resistance. The Fund invests in start-ups, early-stage companies and corporate spin-outs in Europe and the United States, giving priority to first-in-class therapies, covering small molecules, biologics and new modalities, from the early stage of drug development (lead optimization) to the early stages of clinical development (Phase 1).